Medjeduse - Spinal Cord Regeneration Research

Medjeduse is a pioneering startup from the research team at CNRS’s "Axonal Regeneration and Growth", making significant strides in spinal cord repair. In contrast to conventional approaches like exoskeletons and brain interfaces, which primarily address symptoms, Medjeduse's cutting-edge technology focuses on directly tackling spinal cord injuries at their root. The startup's innovative solution responds to the critical need for effective spinal cord injury treatment, a global health concern leading to fatal emergencies and long-term disabilities such as paraplegia and tetraplegia. With over 30,000 new cases annually in the USA and Europe, the global lifetime cost of these injuries amounts to a substantial €70 billion. Medjeduse's groundbreaking work centers on a bioscaffold with a pioneering biomaterial designed to promote spinal cord repair. Through extensive preclinical trials, this technology has demonstrated remarkable success, enabling rats to regain mobility and showcasing unprecedented nerve regeneration. Founded in 2019, the startup has received Non-Equity Assistance investment from AGORANOV on 16 February 2021. Headquartered in France, Medjeduse is dedicated to translating this innovation into a practical therapy, ultimately improving patient recovery and enhancing their quality of life.